BioCentury | Jan 29, 2021
Management Tracks

Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO

...therapy Wuhan Neurophth Biotechnology Ltd. hired Qiutang Li as CSO. She joins Neurophth from the University of Louisville...
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...two or three drug regimen used as standard of care. FCR001 was discovered at the University of Louisville...
BioCentury | Jan 11, 2019
Product R&D

PureTech turns inward

...diseases,” said Bolen. In 2017, PureTech exclusively licensed the milk-derived exosome technology invented at the University of Louisville...
...Boston, Mass. Roche (SIX:ROG; OTCQB:RHHBY), Basel, Switzerland Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), Tokyo, Japan University of Louisville...
BioCentury | Nov 9, 2018
Distillery Therapeutics

Gastrointestinal

...Teng, University of Louisville, Louisville, Ky. email: yun.teng@louisville.edu CONTACT: Huang-Ge Zhang, same affiliation as above email: h0zhan17@louisville.edu Mark Zipkin University of Louisville Colitis exosomes...
BioCentury | Nov 7, 2018
Translation in Brief

Expanding the reach of plant exosomes

...A University of Louisville team has shown how plant-derived exosomes could mobilize the gut microbiome against colitis, broadening...
...tumors. Redman is an associate professor of medicine and associate director of clinical trials at University of Louisville’s...
...because the evolutionary process has created this system of vesicle-mediated traffic.” Mark Zipkin, Staff Writer Alxerion Biotech Corp. University of Louisville Colitis exosomes...
BioCentury | Jul 26, 2018
Targets & Mechanisms

PureTech plumbs the brain

...of compounds to lymphatics. It licensed the technology in 2017 from 3P Biotechnologies Inc., a University of Louisville...
...Health plc (LSE:PRTC), Boston, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland 3P Biotechnologies Inc., Prospect, Ky. University of Louisville...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...could serve as a marker for the anemia. Dana-Farber Cancer Institute ; Stanford University ; University of Louisville...
BioCentury | Oct 1, 2015
Tools & Techniques

NCATS's extracellular revolution

...of Chicago NCATS $969,374 Fruit Exosome-Like Particles for Therapeutic Delivery of Extracellular miRNAs Huang-Ge Zhang University of Louisville...
BioCentury | Apr 30, 2015
Distillery Techniques

Therapeutics: Grapefruit-derived nanoparticles for delivering drugs to sites of inflammation

...Wang, Q. et al. Cancer Res.; published online Apr. 16, 2015 doi:10.1158/0008-5472.CAN-14-3095 CONTACT: Huang-Ge Zhang, University of Louisville...
BioCentury | Nov 13, 2014
Distillery Therapeutics

Indication: Cancer

...Srivastava, A.K. et al. Cancer Res.; published online Sept. 24, 2014; doi:10.1158/0008-5472.CAN-14-1768-A Contact: Haval Shirwan, University of Louisville...
Items per page:
1 - 10 of 44
BioCentury | Jan 29, 2021
Management Tracks

Bilenker leaving Lilly’s Loxo; plus updates from Orchard, Genfit, OncXerna, Medable, Neurophth, Elevian, Biofidelity, BIO

...therapy Wuhan Neurophth Biotechnology Ltd. hired Qiutang Li as CSO. She joins Neurophth from the University of Louisville...
BioCentury | Apr 18, 2019
Company News

Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

...two or three drug regimen used as standard of care. FCR001 was discovered at the University of Louisville...
BioCentury | Jan 11, 2019
Product R&D

PureTech turns inward

...diseases,” said Bolen. In 2017, PureTech exclusively licensed the milk-derived exosome technology invented at the University of Louisville...
...Boston, Mass. Roche (SIX:ROG; OTCQB:RHHBY), Basel, Switzerland Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK), Tokyo, Japan University of Louisville...
BioCentury | Nov 9, 2018
Distillery Therapeutics

Gastrointestinal

...Teng, University of Louisville, Louisville, Ky. email: yun.teng@louisville.edu CONTACT: Huang-Ge Zhang, same affiliation as above email: h0zhan17@louisville.edu Mark Zipkin University of Louisville Colitis exosomes...
BioCentury | Nov 7, 2018
Translation in Brief

Expanding the reach of plant exosomes

...A University of Louisville team has shown how plant-derived exosomes could mobilize the gut microbiome against colitis, broadening...
...tumors. Redman is an associate professor of medicine and associate director of clinical trials at University of Louisville’s...
...because the evolutionary process has created this system of vesicle-mediated traffic.” Mark Zipkin, Staff Writer Alxerion Biotech Corp. University of Louisville Colitis exosomes...
BioCentury | Jul 26, 2018
Targets & Mechanisms

PureTech plumbs the brain

...of compounds to lymphatics. It licensed the technology in 2017 from 3P Biotechnologies Inc., a University of Louisville...
...Health plc (LSE:PRTC), Boston, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland 3P Biotechnologies Inc., Prospect, Ky. University of Louisville...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...could serve as a marker for the anemia. Dana-Farber Cancer Institute ; Stanford University ; University of Louisville...
BioCentury | Oct 1, 2015
Tools & Techniques

NCATS's extracellular revolution

...of Chicago NCATS $969,374 Fruit Exosome-Like Particles for Therapeutic Delivery of Extracellular miRNAs Huang-Ge Zhang University of Louisville...
BioCentury | Apr 30, 2015
Distillery Techniques

Therapeutics: Grapefruit-derived nanoparticles for delivering drugs to sites of inflammation

...Wang, Q. et al. Cancer Res.; published online Apr. 16, 2015 doi:10.1158/0008-5472.CAN-14-3095 CONTACT: Huang-Ge Zhang, University of Louisville...
BioCentury | Nov 13, 2014
Distillery Therapeutics

Indication: Cancer

...Srivastava, A.K. et al. Cancer Res.; published online Sept. 24, 2014; doi:10.1158/0008-5472.CAN-14-1768-A Contact: Haval Shirwan, University of Louisville...
Items per page:
1 - 10 of 44